Subscribe to RSS
DOI: 10.1055/s-0028-1093958
© Georg Thieme Verlag KG Stuttgart · New York
Glucagon Radioimmunoassay Using Antiserum 30K: Interference by Plasma [*]
Publication History
Publication Date:
07 January 2009 (online)
![](https://www.thieme-connect.de/media/hmr/197304/lookinside/thumbnails/10.1055-s-0028-1093958-1.jpg)
Abstract
Studies of a glucagon radioimmunoassay using antiserum 30K suggest that when plasma samples from different individuals are assayed against a single standard curve, an inappropriately wide range of values for fasting human pancreatic glucagon levels is obtained. Evidence is presented that plasma from different subjects contains non-specific factors which interfere with the assay. These factors depress the binding of labeled glucagon but appear to be neither pancreatic glucagon nor an enteric factor with glucagon-like immunoreactivity.
A correction can be made for these interference factors in a given patient because the factors can be quantitated following adsorption of glucagon with charcoal. Fasting immunoreactive glucagon (IRG) levels were determined on the plasma from 13 normal subjects. When all samples were measured against a standard curve using no correction factor the range was 45-295 pg/ml (mean ± standard deviation 131 ± 73.8). Using a correction factor the measured fasting glucagon values were 25-60 pg/ml (mean ± S.D. 43 ± 12.3). Fasting glucagon levels as conventionally determined using antiserum 30K are probably inaccurate, and the use of a correction factor is advisable.
Key words
Glucagon Radioimmunoassay - Antiserum 30K - Interference Factors - Corrected Values
1 This work is supported in part by National Institute of Arthritis and Metabolic Diseases Grants AM 13774-02 and AMO 5205-12, National Science Foundation Grant BO 19636, and research grants from the American Diabetes Association and the John A. Hartford Foundation, Inc.
1 This work is supported in part by National Institute of Arthritis and Metabolic Diseases Grants AM 13774-02 and AMO 5205-12, National Science Foundation Grant BO 19636, and research grants from the American Diabetes Association and the John A. Hartford Foundation, Inc.
2 Recipient of a Daland Fellowship of the American Philosophical Society.